Karyopharm Therapeutics Inc. KPTI
1.62
(0.11)
(6.36%)
as of 25 Sep
- Market cap
- $39.2M
- P/E
- 0.0×
Follow KPTI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
58.11% | 81.86% | 82.70% | 78.98% | |
| (87.24%) | (143.71%) | (150.48%) | (207.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(4,596.86%) | (1,751.91%) | (2,137.35%) | 809.55% | |
Average Days of Receivables |
81.63 | 65.42 | 56.41 | 74.36 | |
Free Cash Flow per Share |
(10.31) | (6.89) | (2.69) | (2.26) | |
Free Cash Flow |
(89.35) | (75.37) | (59.11) | (65.35) | |
Piotroski F-Score |
3.00 | 3.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
263.67% | 3,295.54% | (119.20%) | 432.13% | |
Accounts Receivable Turnover |
4.48 | 5.13 | 5.16 | 4.67 | |
Accounts Payable Turnover |
1.04 | 1.31 | 1.18 | 1.18 | |
Inventory Turnover |
1.34 | 1.36 | 1.43 | 1.34 | |
Average Days of Payables |
339.56 | 245.60 | 260.61 | 463.90 | |
Days of Inventory on Hand |
249.76 | 247.75 | 219.19 | 241.88 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
92.09% | 86.00% | 82.58% | 82.50% | |
Selling, General and Administrative Expense of Revenue |
76.91% | 72.03% | 69.18% | 69.55% | |
Share Based Compensation of Revenue |
9.83% | 9.62% | 8.93% | 7.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.38 | 0.30 | 0.29 | |
Depreciation/Fixed assets |
82.16 | 100.31 | 114.21 | 108.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
16.44 | 13.36 | 6.86 | 5.07 | |
Operating CF per Share |
(10.31) | (6.89) | (2.69) | (2.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(87.43%) | (134.21%) | (129.02%) | (153.28%) |
Columns are period end dates